This article starts with the hormone itself: where glucagon-like peptide-1 comes from, what it does in the minutes after a meal, why it fades so quickly, how medicine reproduced its signal into lasting drugs, and the inherited variation that shapes GLP-1 biology in every body.

This explainer starts with the word agonist, unpacking what it means to switch on the GLP-1 receptor, how the drug versions outlast the natural hormone, where single, dual, and triple agonism differ across the class, and how your inherited genes frame the entire pathway.

Compounded semaglutide explained: the FDA shortage-list context, the 2024 resolution, legitimate 503A compounding vs unregulated sources, and how PlexusDx operates inside the legitimate pathway.

"GLP-1 inhibitors" is one of the most common misnomers in metabolic medicine. This article explains what GLP-1 actually is, why the medications are agonists rather than inhibitors, how DPP-4 inhibitors differ, which compounds are approved, and the genetics of the pathway.

GLP-1 receptor agonists are widely discussed for weight loss. This guide explains how the pathway works, what the published trial programs show, the FDA labeling context as of April 2026, the limitations and contraindications worth knowing, and the genetic variables that sit upstream of every GLP-1 decision.

Natural GLP-1 and "GLP-1 supplements" explained: how dietary inputs influence native GLP-1 release, what the published supplement evidence shows, and the realistic comparison to FDA-approved GLP-1 receptor agonist medications.

Ozempic itself is injection-only, so what does an Ozempic pill actually refer to? This page explains the real oral GLP-1 options, how an oral peptide survives digestion, how pills compare with weekly injections, and the genetic context beneath the choice.

The semaglutide pill search asks what oral GLP-1 options exist and how to take them. This guide covers the single approved oral product, the pipeline, how absorption enhancers work, the strict administration requirements, the cost picture, and the genetic context that applies to any oral GLP-1 conversation.

"GLP-1 drugs for weight loss" searches want the clinical record. This article covers the weight-relevant mechanism, the trial-reported reduction range, the FDA-approved weight-management products, the class safety limits, and the inherited variables that PlexusDx maps behind each individual person's outcome.

This overview covers the tirzepatide injection in the context of weight management, from its GIP and GLP-1 dual-agonist mechanism to what the SURPASS and SURMOUNT programs report, the contraindications worth knowing, and the genetic variables that sit upstream of any protocol decision.

This page focuses on the injectable side of Wegovy, why the drug is delivered by injection, how the once-weekly format supports its GLP-1 mechanism, what the STEP program reported, and who the injection is not right for, finishing with genetic context.

Compounded semaglutide explained: the FDA shortage-list context, the 2024 resolution, legitimate 503A compounding vs unregulated sources, and how PlexusDx operates inside the legitimate pathway.

A plain-language roster of GLP-1 medications: what the drug class does inside the body, which agents carry FDA approval and when, how the injections differ from the single oral tablet, what compounded means, and where your inherited genes fit into the whole picture.

Tirzepatide is widely searched for weight loss. This explainer covers the dual-agonist mechanism, what the SURPASS and SURMOUNT trial programs reported, the FDA-approved indications and labeling timeline, and the contraindications worth knowing — grounding a common search in mechanism and published evidence rather than hype.

GLP-1 receptor agonists became famous for weight loss, but the effect is downstream biology, not a shortcut. This PlexusDx explainer traces the appetite mechanism, reviews what the weight trials actually measured, notes where results reach their limits, and shows how genes like FTO shape the metabolic terrain first.

Wegovy weight loss is a phrase carrying a lot of expectation. This page grounds it in the receptor-level mechanism, the STEP trial findings reported in the literature, the FDA-approved indication, and the contraindications worth knowing, followed by honest genetic context.

A clinical view of Mounjaro for weight loss as of April 2026: the dual GIP/GLP-1 mechanism, what the SURPASS trials actually reported, the FDA labeling and contraindications that govern its use, and the upstream genetic variables that PlexusDx analyzes first, before any protocol decision.

This overview walks through how semaglutide is weighed clinically for weight loss, from its GLP-1 mechanism and the SUSTAIN, STEP, and PIONEER evidence to approved indications, contraindications, and the inherited variables that shape any GLP-1 decision. Facts stay tied to published labeling and literature, not guarantees.

Ozempic (semaglutide) is FDA-approved for type 2 diabetes. This article covers mechanism, evidence base, FDA labeling, safety, and the upstream genetic variables — including TCF7L2, FTO — that shape every type 2 diabetes decision.

An independent head-to-head on tirzepatide and semaglutide: how a GIP/GLP-1 dual agonist differs from a selective GLP-1 agonist, where the FDA indications fall, what the trial programs measured, tolerability, cost drivers, and the pathway-level genetics that apply whichever compound a clinician prescribes.

This independent head-to-head sets semaglutide and tirzepatide side by side across receptor targets, FDA indications, the SURPASS-2 comparison, shared safety signals, and list pricing, then turns to the GIPR, FTO, and MC4R variants that shape the biology both compounds act on.

Retatrutide and tirzepatide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR and FTO — that apply regardless of which compound is prescribed.

Trulicity is a long-acting GLP-1 receptor agonist that many people search in a weight-loss context. This guide walks through its receptor-level mechanism, the AWARD and REWIND trial evidence, its FDA-approved indications, the boxed warning, and the genetic variants that sit upstream of every GLP-1 conversation.

Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.

Semaglutide side effects are well documented in the FDA label and trial programs. This page covers the symptoms most people notice first, the serious risks and boxed warning, the red flags that warrant a call, and how genetics adds pathway context to the tolerability picture.

Retatrutide (retatrutide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Searches for Mounjaro and weight loss usually want two things: how the molecule actually works and what the studies found. This page walks through the dual-receptor mechanism, the SURPASS evidence range, FDA labeling context, who should avoid it, and the genetic variables underneath every GLP-1 decision.

Ozempic reaches most people through the weight-loss conversation, though its FDA label is for type 2 diabetes. This page separates mechanism from marketing: how semaglutide acts at the GLP-1 receptor, what the published trials report, and the genetics beneath it all.

Wegovy is semaglutide, a GLP-1 receptor agonist studied for chronic weight management. This page explains the appetite-and-glucose mechanism, what the STEP trial program reported, the FDA label limits, key safety signals, and how your genetic starting point fits the conversation.

Trulicity (dulaglutide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.